The Filing Desk

Inogen

INGN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

INGN · Last close · November 19, 2026
$5.42
Value Inogen yourself

Inogen's revenue rose 3.9% to $349 million in fiscal 2025. Its operating margin was −8.7%, up from −12.7% a year earlier. Free cash flow was −$14 million, against $3 million a year earlier. The diluted share count rose 12.5%.

INOGEN, INC. Latest fiscal year ended December 31, 2025 10-K filed February 27, 2026 · 0001193125-26-082630 Updated
Revenue
$349M
3.9%
Operating margin
−8.7%
4.0 pts
Net income
−$23M
 
Free cash flow
−$14M
$3M a year earlier
Return on equity
−12.4%
6.5 pts
Market cap
$144M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Inogen does

Inogen is a medical technology company focused on breathing health. Its main products are portable oxygen concentrators, small battery-powered machines that take in the air around a patient and supply extra oxygen, marketed as Inogen One and Inogen Rove. They are used for long-term oxygen therapy by people with chronic lung conditions. It also sells Simeox, a device that helps clear mucus from airways, and has started distributing a stationary oxygen concentrator and CPAP masks for sleep apnea in the United States.

It earns money in three main ways: selling to home medical equipment providers, distributors and resellers; selling directly to consumers; and renting devices directly to consumers. Much of its rental revenue comes from Medicare, private insurers and Medicaid paying for patients.

It entered a collaboration in January 2025 with the Chinese company Jiangsu Yuyue Medical Equipment & Supply, known as Yuwell, to distribute certain respiratory products in the United States. It competes with other makers and distributors of portable oxygen concentrators.

Its biggest risks, as it describes them

  • It faces strong competition from other makers of portable oxygen concentrators and respiratory products.
  • A limited number of customers account for a large part of its sales.
  • Interruptions in the supply of components and products could hurt its manufacturing and sales.
  • Tariffs and trade restrictions could raise its costs and disrupt its supply chain.
  • Much of its revenue depends on reimbursement from Medicare, private payors and Medicaid, and rates or policies could change.
From Inogen's annual report on Form 10-K, filed February 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2019, earnings per share fell 1.0% a year and net income grew 0.6% a year, as new shares raised the share count by 5% and diluted each share's earnings. Inogen then lost money in fiscal 2020, 2021, 2022, 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments246—128114120
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio5.3x4.7x2.9x2.4x3.1x
Quick ratio4.8x4.1x2.5x2.1x2.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Inogen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Inogen shares on the open market, and 1 insider sold $142,519, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 1, 2026Boyer Jennifer M YiEVP Entrprs Enblmnt, Ch HR OffSold plan10,938$6.60$72,191Form 4
May 29, 2026Boyer Jennifer M YiEVP Entrprs Enblmnt, Ch HR OffSold plan10,770$6.53$70,328Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−19.0%7.1%−0.1%
Altman Z''1.061.252.26
Accruals ratio−27.1%−13.4%−3.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Inogen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
InogenFY253.9%−8.7%−3.9%———
Tactile Systems TechnologyFY2512.5%8.9%12.3%12.6%−2.3x8Compare
InModeFY25−6.2%23.1%22.8%———Compare
AngiodynamicsFY269.5%−12.5%0.2%−24.6%—4Compare
PROCEPT BioRoboticsFY2537.2%−33.7%−18.9%−65.4%—5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue203249358362308358377316336349
Revenue growth27.6%23.0%43.6%1.1%−14.8%16.1%5.4%−16.3%6.3%3.9%
Gross profit97121179172138176154127155154
Research and development5579141722212219
Operating income23283820−129−85−109−42−30
Net income20215221−6−6−84−102−36−23
Diluted EPS (US$)0.970.962.300.94−0.27−0.28−3.67−4.42−1.52−0.86
Diluted shares (millions)21222222222223232427
Cash flow
Cash from operations316060413724−38−36−11
Capital expenditure2383463532
Free cash flow295852373318−41−83−14
Dividends paid0000000000
Share buybacks0000000000
Acquisitions040700003000
Stock-based compensation71013981112778
Balance sheet at fiscal year end
Cash and short-term investments114174240209231246—128114120
Debt incl. finance leases——————————
Total assets214275376447462490405326296299
Total liabilities324866103112119108121122106
Shareholders' equity182227310345350370297205174192
Margins and ratios
Gross margin48.0%48.6%49.9%47.5%44.8%49.3%40.7%40.1%46.1%44.2%
Operating margin11.3%11.1%10.6%5.5%−3.9%2.6%−22.6%−34.6%−12.7%−8.7%
Net margin10.1%8.4%14.5%5.8%−1.9%−1.8%−22.2%−32.5%−10.7%−6.5%
Free cash flow margin14.4%23.1%14.5%10.3%10.6%5.1%−10.8%−2.7%0.8%−3.9%
Rule of 40 (growth + FCF margin)42.0%46.1%58.1%11.4%−4.2%21.1%−5.5%−19.0%7.1%−0.1%
Return on capital——————————
Return on equity13.0%10.3%19.3%6.4%−1.7%−1.8%−25.1%−40.8%−18.9%−12.4%
Return on assets10.9%8.6%15.9%5.1%−1.3%−1.3%−18.7%−28.0%−11.5%−7.7%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Inogen's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Inogen.